Literature DB >> 12186458

Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.

Arun P Amar1, William T Couldwell, Joseph C T Chen, Martin H Weiss.   

Abstract

OBJECT: Prolactin-secreting pituitary adenomas may be managed by surgery, medication, radiotherapy, or observation. The authors reviewed a consecutive series of patients who were followed for at least 5 years after surgery to assess the prognostic significance of preoperative factors (tumor size and prolactin level) and an immediate postoperative factor (prolactin level obtained the morning after surgery) on long-term hormonal outcome, thereby clarifying the indications for surgical removal of tumor, the definition of successful treatment outcomes, and the nature of "recurrent" tumors.
METHODS: Between 1979 and 1991, 241 patients with prolactinomas underwent transsphenoidal resection. Nineteen patients were lost to follow-up review, whereas the remaining 222 patients underwent measurement of their prolactin levels on postoperative Day 1 (POD 1), at 6 and 12 weeks, and every 6 months thereafter for a minimum of 5 years. On POD 1, prolactin levels in 133 patients (Group 1) were lower than 10 ng/ml, in 43 patients (Group 2) between 10 and 20 ng/ml, and in 46 patients (Group 3) higher than 20 ng/ml. At 6 and 12 weeks, normal prolactin levels (< or = 20 ng/ml) were measured in 132 (99%) of the 133 patients in Group 1 but only in 32 (74%) of the 43 patients in Group 2. By 5 years postoperatively, normal levels of prolactin were still measured in 130 patients (98%) in Group 1 compared with only five patients (12%) in Group 2. No patient with a prolactin level lower than 3 ng/ml on POD 1 was found to have an elevated hormone level at 5 years. The likelihood of a long-term chemical cure was greater for patients with microadenomas (91% cure rate) than for those with macroadenomas (33%). Preoperative prolactin levels also correlated with hormonal outcome.
CONCLUSIONS: Prolactin levels lower than 10 ng/ml on POD 1 predict a long-term chemical cure in patients with microadenomas (100% cure rate) and those with macroadenomas (93% cure rate). In contrast, a cure is not likely to be obtained in patients with normal levels ranging between 10 and 20 ng/ml on POD 1 if they harbor macroadenomas (0% cure rate). A recurrence reported several years after surgery probably represents the presence of persistent tumor that was not originally removed. If the initial operation was performed by an experienced surgeon, however, reoperation is not likely to yield a chemical cure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186458     DOI: 10.3171/jns.2002.97.2.0307

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Medical and surgical management of microprolactinoma.

Authors:  William T Couldwell; Martin H Weiss
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

2.  Treatment and prognosis of pituitary adenomas in children.

Authors:  Kai Shu; Lin Han; Huaqiu Zhang; Ting Lei; Ling Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 4.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

5.  Utility of intraoperative ultrasonography for resection of pituitary adenomas: a comparative retrospective study.

Authors:  Mohammed Alshareef; Stephen Lowe; Yeonhee Park; Bruce Frankel
Journal:  Acta Neurochir (Wien)       Date:  2021-01-05       Impact factor: 2.216

6.  Surgical management considerations in cystic prolactinomas-a single center case series.

Authors:  Edin Nevzati; Grégoire P Chatain; Steven B Carr; Kevin O Lillehei; Janice M Kerr
Journal:  Endocrine       Date:  2019-11-26       Impact factor: 3.633

Review 7.  Surgery for prolactinomas: a better choice?

Authors:  Jürgen Honegger; Isabella Nasi-Kordhishti; Nuran Aboutaha; Sabrina Giese
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

8.  Prolactinomas in children under 14. Clinical presentation and long-term follow-up.

Authors:  Yang Liu; Yong Yao; Bing Xing; Wei Lian; Kan Deng; Ming Feng; Renzhi Wang
Journal:  Childs Nerv Syst       Date:  2015-03-15       Impact factor: 1.475

9.  Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery.

Authors:  Na Yi; Lijin Ji; Qi Zhang; Shuo Zhang; Xiaoxia Liu; Xuefei Shou; Bin Lu
Journal:  Endocrine       Date:  2018-06-22       Impact factor: 3.633

Review 10.  Postoperative assessment of the patient after transsphenoidal pituitary surgery.

Authors:  John C Ausiello; Jeffrey N Bruce; Pamela U Freda
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.